Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics has received FDA alignment on the design of its registrational trial for VP-001, a drug candidate aimed at treating Retinitis Pigmentosa type 11 (RP11), a blinding eye disease. The FDA’s acceptance of PYC’s trial design, including the use of a sham control arm and specific inclusion criteria, marks a significant step towards a New Drug Application. This progress could enhance PYC’s positioning in the biotechnology industry by advancing its clinical pipeline and potentially offering a new treatment option for RP11 patients.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company focused on creating precision RNA therapies for genetic diseases. The company utilizes a proprietary drug delivery platform to enhance the potency of its medicines, targeting monogenic diseases which have a higher likelihood of success in clinical development.
Average Trading Volume: 443,644
Technical Sentiment Signal: Hold
Current Market Cap: A$670.7M
Learn more about PYC stock on TipRanks’ Stock Analysis page.